Rebaz Haji Ali, Shano M. Ali, Rawa M. Ali, Soran H. Tahir, Shad Nasir Mohammed, Dana T. Gharib, Zana Baqi Najmadden, Hoshmand R. Asaad and 2 more
Introduction Desmoplastic small round cell tumor (DSRCT) is an ultra-rare and highly aggressive mesenchymal tumor that primarily affects the peritoneum, and to a lesser extent, the visceral organs in the abdominal cavity. This study presents a case of a patient who has been diagnosed with DSRCT and has been managed…
Desmoplastic Small Round Cell Tumor: A Case Report
Rebaz Haji Ali, Shano M. Ali, Rawa M. Ali, Soran H. Tahir, Shad Nasir Mohammed, Dana T. Gharib, Zana Baqi Najmadden, Hoshmand R. Asaad and 2 more
IntroductionDesmoplastic small round cell tumor (DSRCT) is an ultra-rare and highly aggressive mesenchymal tumor that primarily affects the peritoneum, and to a lesser extent, the visceral organs in the abdominal cavity. This study presents a case of a patient who has been diagnosed with DSRCT and has been managed with VAC-IE chemotherapy.
Case presentationA 43-year-old male presented with a complaint of epigastric pain for 20 days but no other clinical symptoms. A CT scan and an abdominal ultrasound showed multiple lesions in the peritoneum, and biopsies were taken from all the sites. Histological analysis revealed nests of small blue round cells surrounded by an abundant stroma. Immunohistochemistry results confirmed the disease to be a desmoplastic small round cell tumor.
ConclusionThis disease is yet to be fully understood, and the response of our case to VAC-IE chemotherapy has shown promising outcomes. This form of treatment can be further studied to establish and help in finding a treatment with a better prognosis.
Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more
Abstract Introduction Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or…
Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature
Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more
Introduction Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or not bevacizumab is administered. Immunotherapy-based immune checkpoint inhibitors demonstrated a promising antitumor efficacy in a variety of cancer types. This is a systematic review of the current role of durvalumab in the management of this condition.
Methods A systematic search was carried out through the databases and search engines. Regardless of study design, line of therapy, mode of therapy, or Eastern Cooperative Oncology Group (ECOG) performance status, studies that primarily focused on the outcomes of treating this disease with durvalumab were eligible for inclusion. After the initial and full-text screenings, five studies were reviewed.
Results The median age of the total 235 patients was 66.9 years. Males comprised 174 (74.04%) of the cases, with 61 (25.95%) cases being female. The Epithelioid mesothelioma subtype accounted for 194 (82.55%) of the patients. Durvalumab, in combination with pemetrexed cisplatin/carboplatin as therapy, was used in 109 (48.38%) cases. Durvalumab and tremelimumab were used in the treatment of 40 (17.02%) cases, of which 17 (7.23%) had retreatment with both immunotherapies. Among the patients who underwent durvalumab treatment, 69 (29.36% ) of the individuals previously received carboplatin/pemetrexed and cisplatin/pemetrexed.
Conclusion Durvalumab can be utilized as an effective alternative for malignant pleural mesothelioma treatment, providing positive results and acceptable safety profiles.
Zardasht Mahmud Ahamed, Hardi Mohammed Dhahir, Miran Mawlood Mohammed, Rebaz Haji Ali, Shko H. Hassan, Aso S. Muhialdeen, Yadgar Abdulhameed Saeed, Mariwan L. Fatah and 9 more
Introduction This study aimed to evaluate the performance of Chat Generative Pre-Trained Transformer (ChatGPT), an AI-powered chatbot, in providing treatment recommendations for head and neck nodules. Methods Ten diverse cases were examined, including individuals with varying ages and conditions such as thyroid…
Comparative Analysis of ChatGPT and Human Decision-Making in Thyroid and Neck Swellings: A Case-Based Study
Zardasht Mahmud Ahamed, Hardi Mohammed Dhahir, Miran Mawlood Mohammed, Rebaz Haji Ali, Shko H. Hassan, Aso S. Muhialdeen, Yadgar Abdulhameed Saeed, Mariwan L. Fatah and 9 more
IntroductionThis study aimed to evaluate the performance of Chat Generative Pre-Trained Transformer (ChatGPT), an AI-powered chatbot, in providing treatment recommendations for head and neck nodules.
MethodsTen diverse cases were examined, including individuals with varying ages and conditions such as thyroid nodules and suspicious neck lesions. The decisions made by ChatGPT were compared to those of physicians. Data were collected from the Smart Health Tower on May 2, 2023.
ResultsAnalysis of the cases revealed that ChatGPT provided recommendations that aligned with physicians' decisions in seven cases. However, disparities were observed in three cases (N5, N8, N10). Discrepancies were influenced by factors such as nodule size, thyroid function, and the presence of associated symptoms.
ConclusionThe findings suggest that ChatGPT can assist healthcare professionals in formulating individualized diagnoses and treatment strategies for head and neck nodules. However, further research is needed to validate the performance of ChatGPT in larger patient populations and assess its long-term impact on patient outcomes.
